307 related articles for article (PubMed ID: 16183853)
41. Investigation of the interaction of a putative allosteric modulator, N-(2,3-diphenyl-1,2,4-thiadiazole-5-(2H)-ylidene) methanamine hydrobromide (SCH-202676), with M1 muscarinic acetylcholine receptors.
Lanzafame A; Christopoulos A
J Pharmacol Exp Ther; 2004 Mar; 308(3):830-7. PubMed ID: 14617684
[TBL] [Abstract][Full Text] [Related]
42. Strategies for the identification of allosteric modulators of G-protein-coupled receptors.
Burford NT; Watson J; Bertekap R; Alt A
Biochem Pharmacol; 2011 Mar; 81(6):691-702. PubMed ID: 21184747
[TBL] [Abstract][Full Text] [Related]
43. Accelerated structure-based design of chemically diverse allosteric modulators of a muscarinic G protein-coupled receptor.
Miao Y; Goldfeld DA; Moo EV; Sexton PM; Christopoulos A; McCammon JA; Valant C
Proc Natl Acad Sci U S A; 2016 Sep; 113(38):E5675-84. PubMed ID: 27601651
[TBL] [Abstract][Full Text] [Related]
44. Enantiomeric N-methyl-4-piperidyl benzilates as muscarinic receptor ligands: Radioligand binding studies and docking studies to models of the three muscarinic receptors M1, M2 and M3.
Selent J; Brandt W; Pamperin D; Göber B
Bioorg Med Chem; 2006 Mar; 14(6):1729-36. PubMed ID: 16290166
[TBL] [Abstract][Full Text] [Related]
45. A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand.
Valant C; Gregory KJ; Hall NE; Scammells PJ; Lew MJ; Sexton PM; Christopoulos A
J Biol Chem; 2008 Oct; 283(43):29312-21. PubMed ID: 18723515
[TBL] [Abstract][Full Text] [Related]
46. Identification of orthosteric and allosteric site mutations in M2 muscarinic acetylcholine receptors that contribute to ligand-selective signaling bias.
Gregory KJ; Hall NE; Tobin AB; Sexton PM; Christopoulos A
J Biol Chem; 2010 Mar; 285(10):7459-74. PubMed ID: 20051519
[TBL] [Abstract][Full Text] [Related]
47. Movement of 'gating charge' is coupled to ligand binding in a G-protein-coupled receptor.
Ben-Chaim Y; Chanda B; Dascal N; Bezanilla F; Parnas I; Parnas H
Nature; 2006 Nov; 444(7115):106-9. PubMed ID: 17065983
[TBL] [Abstract][Full Text] [Related]
48. Docking analyses on human muscarinic receptors: unveiling the subtypes peculiarities in agonists binding.
Vistoli G; Pedretti A; Dei S; Scapecchi S; Marconi C; Romanelli MN
Bioorg Med Chem; 2008 Mar; 16(6):3049-58. PubMed ID: 18182302
[TBL] [Abstract][Full Text] [Related]
49. Seven transmembrane receptors as nature's prototype allosteric protein: de-emphasizing the geography of binding.
Kenakin TP
Mol Pharmacol; 2008 Sep; 74(3):541-3. PubMed ID: 18583453
[TBL] [Abstract][Full Text] [Related]
50. Cholinergic nicotinic receptors: competitive ligands, allosteric modulators, and their potential applications.
Romanelli MN; Gualtieri F
Med Res Rev; 2003 Jul; 23(4):393-426. PubMed ID: 12710018
[TBL] [Abstract][Full Text] [Related]
51. Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology.
Leach K; Sexton PM; Christopoulos A
Trends Pharmacol Sci; 2007 Aug; 28(8):382-9. PubMed ID: 17629965
[TBL] [Abstract][Full Text] [Related]
52. The impact of orthosteric radioligand depletion on the quantification of allosteric modulator interactions.
Avlani VA; McLoughlin DJ; Sexton PM; Christopoulos A
J Pharmacol Exp Ther; 2008 Jun; 325(3):927-34. PubMed ID: 18322151
[TBL] [Abstract][Full Text] [Related]
53. Exploration of the orthosteric/allosteric interface in human M1 muscarinic receptors by bitopic fluorescent ligands.
Daval SB; Kellenberger E; Bonnet D; Utard V; Galzi JL; Ilien B
Mol Pharmacol; 2013 Jul; 84(1):71-85. PubMed ID: 23604140
[TBL] [Abstract][Full Text] [Related]
54. Allosteric modulation of G protein-coupled receptors: a pharmacological perspective.
Keov P; Sexton PM; Christopoulos A
Neuropharmacology; 2011 Jan; 60(1):24-35. PubMed ID: 20637785
[TBL] [Abstract][Full Text] [Related]
55. Identification of a Novel Allosteric Site at the M
Burger WAC; Gentry PR; Berizzi AE; Vuckovic Z; van der Westhuizen ET; Thompson G; Yeasmin M; Lindsley CW; Sexton PM; Langmead CJ; Tobin AB; Christopoulos A; Valant C; Thal DM
ACS Chem Neurosci; 2021 Aug; 12(16):3112-3123. PubMed ID: 34351123
[TBL] [Abstract][Full Text] [Related]
56. Allosteric modulation of G protein-coupled receptors.
May LT; Leach K; Sexton PM; Christopoulos A
Annu Rev Pharmacol Toxicol; 2007; 47():1-51. PubMed ID: 17009927
[TBL] [Abstract][Full Text] [Related]
57. Amiloride derivatives and a nonpeptidic antagonist bind at two distinct allosteric sites in the human gonadotropin-releasing hormone receptor.
Heitman LH; Ye K; Oosterom J; Ijzerman AP
Mol Pharmacol; 2008 Jun; 73(6):1808-15. PubMed ID: 18344315
[TBL] [Abstract][Full Text] [Related]
58. Molecular mechanisms of bitopic ligand engagement with the M1 muscarinic acetylcholine receptor.
Keov P; López L; Devine SM; Valant C; Lane JR; Scammells PJ; Sexton PM; Christopoulos A
J Biol Chem; 2014 Aug; 289(34):23817-37. PubMed ID: 25006252
[TBL] [Abstract][Full Text] [Related]
59. Immunologic mimicry by a monoclonal antibody of the tricyclic anti-depressants' binding site on muscarinic acetylcholine receptors.
Marullo S; Hoebeke J; Guillet JG; Andre C; Strosberg AD
J Immunol; 1987 Jan; 138(2):524-6. PubMed ID: 2432128
[TBL] [Abstract][Full Text] [Related]
60. Critical amino acid residues of the common allosteric site on the M2 muscarinic acetylcholine receptor: more similarities than differences between the structurally divergent agents gallamine and bis(ammonio)alkane-type hexamethylene-bis-[dimethyl-(3-phthalimidopropyl)ammonium]dibromide.
Huang XP; Prilla S; Mohr K; Ellis J
Mol Pharmacol; 2005 Sep; 68(3):769-78. PubMed ID: 15937215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
